Participated · Series B · Mar 2026

Giraffe360 provides an integrated platform that pairs proprietary capture hardware with AI-powered software to create complete property media kits from a single visit. Its system generates HDR photography, virtual tours, LiDAR-based 2D and 3D floor plans, video content, property websites, virtual staging, and social media assets. By consolidating capture-to-delivery workflows into one system, the company aims to accelerate time-to-market for listings and improve listing quality while supporting photographers and real estate agents in growing their business. The company plans to continue developing its AI capabilities and expand product features and geographic operations following the Series B. The article does not disclose revenue, user metrics, or founding year.

Led · Seed · Oct 2025

Milvus Advanced is an Oxford-based deep-tech startup that designs nanoalloy materials capable of matching or exceeding the properties of platinum-group and other critical metals. Its proprietary, independently validated alloys offer superior durability and performance in electrochemical and optoelectronic systems while relying only on abundant elements. Operating on a B2B model, the company targets sectors such as clean energy, transport, chemical manufacturing and electronics, where cost, performance and sustainability intersect. By removing dependence on geopolitically fragile and expensive raw materials, Milvus aims to stabilize supply chains and lower environmental impact. Early pilots are underway with global electrolyser OEMs and chemical manufacturers, showing initial commercial traction. Armed with fresh capital, the firm intends to scale production, grow its team, enter the U.S. market for manufacturing and partnerships, and expand R&D into additional material systems. No revenue or user metrics have yet been disclosed, but management positions Milvus at the forefront of a new materials revolution that underpins the energy transition.

Participated · Series A · Oct 2025

Finster AI develops AI-native infrastructure designed for the next generation of investment banking workflows, focusing on trusted data, secure environments, and deep workflow integration. The company positions its platform to be purpose-built for how financial institutions work, aiming to support end-to-end banking workflows. Following the Series B strategic investments from UBS Investment Bank and FactSet, Finster AI plans to expand the scale and depth of its offering. The announcement frames the investments as endorsements of the company's vision for AI-native workflow infrastructure. No revenue, user, founding year, location, or valuation metrics were provided in the announcement.

Participated · Series A · Oct 2025

Valink Therapeutics engineers next-generation oncology therapeutics that combine bispecific antibody technology with antibody-drug conjugates to improve efficacy, safety, and precision. Its proprietary discovery platform and V-gate™ approach expand the design space for bsADCs, enabling fine-tuned target control and an improved therapeutic index compared with current ADC technologies. Beyond bsADCs, the company is building a suite of multispecific or multifunctional ADCs and multivalent agonists to address additional therapeutic needs. Valink is advancing two first-in-class oncology programs for solid tumors, including colorectal cancer, which are now moving toward preclinical development. Proceeds from recent financing will fund this pipeline progression and further platform development. The company operates from its headquarters in Cambridge, Massachusetts, with R&D facilities in the United Kingdom.

Led · Series A · Oct 2025

Founded in 2021 by Alexandros Pantalis and Adèle James, Phagos engineers bacteriophage (phage) treatments through a proprietary platform that combines microbiology with artificial intelligence. Its patented AI analyses complete phage and bacterial genomes to predict interactions and design precise, adaptable therapies as pathogens evolve. The company’s first commercial focus is veterinary medicine, where it has already secured regulatory authorisation to market personalised phage-based treatments aimed at reducing antibiotic use in livestock. Longer term, Phagos intends to expand these solutions to human health applications. With antimicrobial resistance driving millions of deaths and heavy economic costs, management positions the technology as a scalable global standard for bacterial infection control. The recent €25 million Series A financing provides capital to scale veterinary product deployment, advance the next generation of its AI, and grow the team to support market launches and international expansion. No operating metrics such as revenue or user counts were disclosed in the article.